We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Partnership to Develop and Deliver Solutions for Interpreting Diagnostic Tests

By LabMedica International staff writers
Posted on 08 Oct 2012
Ingenuity Systems (Redwood City, CA, USA) has announced a partnership with Life Technologies Corporation (Carlsbad, CA, USA) to develop and deliver a joint solution for rapid, high-confidence interpretation of molecular profiling information from Life Technologies' molecular diagnostic tests.

Ingenuity Systems’ unique software and content will be provided to interpreting physicians, such as molecular pathologists and medical geneticists, in a dedicated portal, which will initially be made available for Life Technologies' emerging line of cancer diagnostic tests. More...
Users of this interpretation portal will be able to review disease management guidelines, identify clinical trials, and find cutting-edge insights from biomedical research. The Ingenuity Systems solution will be made available in context with other software and database solutions to provide a wide range of information. Interpreting physicians will leverage the comprehensive, expert-curated “Ingenuity Knowledge Base” of biomedical content. Results of the interpretation process will then be conveyed through a reporting portal to treating physicians. While these tools will not provide medical decisions to treating physicians, they will provide contextual information that could often help identify suitable treatment options based on biological factors of an individual patient's disease.

"Advanced diagnostic tests [...] will deliver increasingly complex information about a patient's disease. It is essential that those results be made relevant to interpreting physicians by making all possible contextual information available in a single interpretation portal. We believe that Ingenuity Systems provides unique and valuable information, and we are pleased to work with them to shape the repertoire of information that the physicians interpreting our tests can employ to understand the biology of their patient's disease," said Ronnie Andrews, president, Life Technologies’ Medical Sciences division.

"With its broad technology platforms and targeted acquisitions Life Technologies is rapidly emerging as a leading provider of clinical diagnostic solutions," said Jake Leschly, CEO, Ingenuity Systems; "Our unique content and applications address a critical bottleneck in the development of the clinical diagnostic market and our partnership with [Life Technologies] enables a unique and powerful end-to-end solution for the molecular pathologist."

Related Links:
Ingenuity Systems
Life Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.